<?xml version="1.0" encoding="UTF-8"?>
<rr:ResultsReport xmlns:rr="http://integration.foundationmedicine.com/reporting" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd">
  <rr:CustomerInformation>
    <rr:ReferenceID>01-2023-00030983</rr:ReferenceID>
    <rr:CSN />
    <rr:TRF>ORD-1667994-01</rr:TRF>
    <rr:MRN>17051911 PF23084</rr:MRN>
    <rr:PhysicianId>109266</rr:PhysicianId>
    <rr:NPI />
  </rr:CustomerInformation>
  <rr:ResultsPayload>
    <FinalReport xmlns:xsd="http://www.w3.org/2001/XMLSchema" StagingId="1345342" clinicalId="1346687" xsi:noNamespaceSchemaLocation="http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd">
      <Application>
        <ApplicationSettings>
          <ApplicationSetting>
            <Name>Statement</Name>
            <Value />
          </ApplicationSetting>
        </ApplicationSettings>
      </Application>
      <DemographicCorrectionDate />
      <ReportId>ORD-1667994-01</ReportId>
      <SampleName>US1589887.01</SampleName>
      <Version>0</Version>
      <Sample>
        <FM_Id>ORD-1667994-01</FM_Id>
        <SampleId>US1589887.01</SampleId>
        <BlockId>S112-66168G (PF23084)</BlockId>
        <TRFNumber>ORD-1667994-01</TRFNumber>
        <TestType>FoundationOne CDX</TestType>
        <SpecFormat>Slide Deck</SpecFormat>
        <ReceivedDate>2023-07-05</ReceivedDate>
        <processSites>
          <processSite address="150 Second St., 1st Floor, Cambridge, MA 02141" cliaNumber="22D2027531" locationID="1" locationName="Cambridge" processID="1" processName="LC" />
          <processSite address="150 Second St., 1st Floor, Cambridge, MA 02141" cliaNumber="22D2027531" locationID="1" locationName="Cambridge" processID="1" processName="Extracted DNA" />
        </processSites>
      </Sample>
      <PMI>
        <ReportId>ORD-1667994-01</ReportId>
        <MRN>17051911 PF23084</MRN>
        <FullName>Huang, Chien Chung</FullName>
        <FirstName>Chien Chung</FirstName>
        <LastName>Huang</LastName>
        <SubmittedDiagnosis>Colon adenocarcinoma (CRC)</SubmittedDiagnosis>
        <Gender>Female</Gender>
        <DOB>1951-01-04</DOB>
        <OrderingMD>Yeh, Yi-Chen</OrderingMD>
        <OrderingMDId>109266</OrderingMDId>
        <Pathologist>Not Provided</Pathologist>
        <CopiedPhysician1 />
        <MedFacilName>Taipei Veterans General Hospital</MedFacilName>
        <MedFacilID>205872</MedFacilID>
        <SpecSite>Ovary</SpecSite>
        <CollDate>2023-03-21</CollDate>
        <ReceivedDate>2023-07-05</ReceivedDate>
        <CountryOfOrigin>TW</CountryOfOrigin>
      </PMI>
      <PertinentNegatives>
        <PertinentNegative>
          <Gene>BRAF</Gene>
        </PertinentNegative>
        <PertinentNegative>
          <Gene>KRAS</Gene>
        </PertinentNegative>
        <PertinentNegative>
          <Gene>NRAS</Gene>
        </PertinentNegative>
        <PertinentNegative>
          <Gene>ERBB2</Gene>
        </PertinentNegative>
      </PertinentNegatives>
      <Summaries alterationCount="7" clinicalTrialCount="0" resistiveCount="0" sensitizingCount="2" />
      <VariantProperties>
        <VariantProperty geneName="MSH6" isVUS="true" variantName="K1358fs*2" />
        <VariantProperty geneName="TSC1" isVUS="true" variantName="Q654E" />
      </VariantProperties>
      <priorTests />
      <Genes>
        <Gene>
          <Name>KRAS</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>wildtype</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="wildtype" />
              </AlterationProperties>
              <Interpretation>KRAS encodes a member of the RAS family of small GTPases. Activating mutations in RAS genes can cause uncontrolled cell proliferation and tumor formation (Pylayeva-Gupta et al., 2011; 21993244, Kahn et al., 1987; 3310850). No alterations in KRAS were identified in this case. Approximately 50-65% of colorectal cancers (CRCs) have been reported to lack KRAS mutations (Lievre et al., 2006; 16618717, De Roock et al., 2011; 21163703, Chen et al., 2014; 25367198, Li et al., 2015; 25929517, Hu et al., 2016; 27977612, Zekri et al., 2017; 28218784, Staudacher et al., 2017; 29048416, Wang et al., 2018; 29705968, Guo et al., 2018; 29666387). Numerous studies have reported that KRAS wild-type status is associated with decreased metastasis, better clinicopathological features, and longer survival of patients with CRC (Chen et al., 2014; 25367198, Li et al., 2015; 25929517, Hu et al., 2016; 27977612, MÃ¡rmol et al., 2017; 28106826, Zekri et al., 2017; 28218784, Kwak et al., 2017; 28858102). Lack of mutations in KRAS or NRAS is associated with clinical benefit of treatment with EGFR-targeting antibodies cetuximab (Van Cutsem et al., 2011; 21502544, Bokemeyer et al., 2011; 21228335, Karapetis et al., 2008; 18946061, De Roock et al., 2008; 17998284) or panitumumab (Douillard et al., 2014; 24718886, Douillard et al., 2012; 24024839, Amado et al., 2008; 18316791) for patients with CRC. Therefore, these agents are indicated to treat patients with CRC lacking such mutations (NCCN Colon Cancer Guidelines, v3.2022, Rectal Cancer Guidelines, v4.2022).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies>
                <Therapy>
                  <Name />
                  <GenericName>Cetuximab</GenericName>
                  <FDAApproved>true</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Cetuximab is a monoclonal antibody that targets EGFR. It is FDA approved for the treatment of head and neck squamous cell carcinoma (HNSCC) and KRAS-wild-type, EGFR-expressing metastatic colorectal cancer (CRC). Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; Therapies targeting EGFR, including cetuximab, have been shown to have significant clinical activity for patients with CRC (Bokemeyer et al., 2011; 21228335, Cunningham et al., 2004; 15269313, De Roock et al., 2008; 17998284, Jonker et al., 2007; 18003960, Karapetis et al., 2008; 18946061, Van Cutsem et al., 2011; 21502544); wild-type KRAS and NRAS are predictive biomarkers for the efficacy of cetuximab in metastatic CRC (NCCN Colon Cancer Guidelines, v3.2022, NCCN Rectal Cancer Guidelines, v4.2022). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; Cetuximab has been shown to improve OS, PFS, and response rate for patients with KRAS-wildtype colorectal cancer (CRC), both in combination with FOLFIRI, FOLFOX4, or irinotecan (Van Cutsem et al., 2011; 21502544, Bokemeyer et al., 2011; 21228335, Jonker et al., 2007; 18003960, Cunningham et al., 2004; 15269313, Papamichael et al., 2022; 35033994) and as monotherapy for chemotherapy-refractory patients (De Roock et al., 2008; 17998284, Karapetis et al., 2014; 24218517). The Phase 3 study STRATEGIC-1 reported a similar duration of disease control (DDC) for patients with unresectable metastatic CRC (mCRC) and KRAS-, NRAS-, and BRAF-wildtype status treated with mFOLFOX-bevacizumab alternated with a cetuximab regimen in first or second line, respectively (overall DDC 22.5 vs. 23.5 months); in addition, the study reported similar OS (37.8 vs. 34.4 months) and higher numerical ORR for patients treated with cetuximab in the first line followed by mFOLFOX-bevacizumab compared with those receiving EGFR-directed antibodies in the second or third line (Chibaudel et al., 2022; ASCO Abstract 3504). A prospective study of cetuximab monotherapy for patients with KRAS-, NRAS-, and BRAF-wildtype mCRC reported 11% (2/19) PRs and 58% (11/19) SDs (Moiseyenko et al., 2018; 29470838). The Phase 2 AVETUX trial of cetuximab combined with avelumab and mFOLFOX6 for patients with RAS- and BRAF-wildtype mCRC resulted in an ORR of 81% (4 CR and 27 PRs, n=37) and a DCR of 89% (Stein et al., 2021; 34315821). In the Phase 3 ASPECCT study, panitumumab was found to be non-inferior to cetuximab with respect to median OS (10.4 vs. 10.0 months, HR=0.97) for patients with previously treated KRAS exon 2 wildtype metastatic colorectal cancer; median PFS was also similar between the two treatment groups (4.4 vs. 4.1 months, HR=1.00)(Price et al., 2014; 24739896). In a similar patient population, a Phase 2 study of combination panitumumab and irinotecan versus combination cetuximab and irinotecan also demonstrated non-inferiority with respect to median PFS (5.4 vs. 4.3 months, HR = 0.64) and median OS (14.9 vs. 11.5 months, HR=0.66)(Sakai et al., 2020; 32526634). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Panitumumab</GenericName>
                  <FDAApproved>true</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Panitumumab is a monoclonal antibody that targets EGFR. It is FDA approved to treat KRAS wild-type and NRAS wild-type metastatic colorectal cancer (CRC) combined with chemotherapy or as monotherapy for patients who have progressed on prior chemotherapy. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; Therapies targeting EGFR, including panitumumab, have been shown to have significant clinical activity for patients with CRC (Douillard et al., 2014; 24718886, Price et al., 2014; 24739896, Van Cutsem et al., 2007; 17470858); wild-type KRAS and NRAS are predictive biomarkers for the efficacy of panitumumab in metastatic CRC (NCCN Colon Cancer Guidelines v3.2022)(NCCN Rectal Cancers Guidelines, v4.2022). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; Panitumumab has been shown to improve OS, PFS, and ORR for patients with KRAS-wildtype colorectal cancer (CRC), both in combination with FOLFOX4, FOLFIRI, irinotecan, or best supportive care (Douillard et al., 2014; 24718886, Peeters et al., 2015; 26341920, Watanabe et al., 2022; 35723084, Kim et al., 2018; 29703606, Shitara et al., 2016; 27712015), and as monotherapy for chemotherapy-refractory patients (Price et al., 2014; 24739896, Van Cutsem et al., 2007; 17470858, Peeters et al., 2013; 23325582). The Phase 3 PARADIGM trial comparing panitumumab plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 as first-line treatment for patients with RAS-wildtype left-sided metastatic CRC demonstrated that treatment with panitumumab significantly improved median OS (mOS; 36.2 months vs. 31.3 months) compared with bevacizumab (Yoshino et al., 2022; ASCO Abstract LBA1). A Phase 2 trial reported that, for patients with unresectable RAS-wildtype colorectal adenocarcinoma treated with panitumumab plus FOLFOX4, maintenance with a combination of panitumumab plus fluorouracil and leucovorin was superior to panitumumab monotherapy (10-month PFS OF 59% vs. 49%)(Pietrantonio et al., 2019; 31268481). In the Phase 3 ASPECCT study, panitumumab was found to be non-inferior to cetuximab with respect to median OS (10.4 vs. 10.0 months, HR=0.97) for patients with previously treated KRAS exon 2 wildtype metastatic colorectal cancer; median PFS was also similar between the two treatment groups (4.4 vs. 4.1 months, HR=1.00)(Price et al., 2014; 24739896). In a similar patient population, a Phase 2 study of combination panitumumab and irinotecan versus combination cetuximab and irinotecan also demonstrated non-inferiority with respect to median PFS (5.4 vs. 4.3 months, HR = 0.64) and median OS (14.9 vs. 11.5 months, HR=0.66)(Sakai et al., 2020; 32526634). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
              </Therapies>
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>Microsatellite status</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>Cannot Be Determined</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="Cannot Be Determined" />
              </AlterationProperties>
              <Interpretation>Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. Approximately 10-15% of colorectal cancers (CRCs) are MSI-high (MSI-H), 8-16% are MSI-low (MSI-L), and the remaining majority are microsatellite-stable (MSS) (Jass et al., 1999; 10562815, Guastadisegni et al., 2010; 20627535, Pawlik et al., 2004; 15528785, Kocarnik et al., 2015; 26337942, Cancer Genome Atlas Network., 2012; 22810696, Lal et al., 2015; 25949894). Multiple studies have shown that MSI-H CRCs have a better prognosis than MSI-low (MSI-L) or microsatellite stable (MSS) tumors (Samowitz et al., 2001; 11535541, Elsaleh and Iacopetta, 2001; 12445368, Brueckl et al., 2003; 12820457, Guidoboni et al., 2001; 11438476, Gryfe et al., 2000; 10631274, Sinicrope et al., 2006; 16952542, Guastadisegni et al., 2010; 20627535, Laghi and Malesci, 2012; 22722556). MSI-H CRCs are associated with certain pathologic and molecular features, including poor differentiation, right-sided and mucinous tumors, increased numbers of tumor infiltrating lymphocytes, diploidy, and a relatively high frequency of BRAF mutations (Kocarnik et al., 2015; 26337942, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). The prognostic implications of MS-Equivocal status for patients with colorectal cancer (CRC) have not been evaluated in published studies. One study reported that microsatellite instability-low (MSI-L) tumors occur more frequently in early-stage CRC than advanced CRC (Kambara et al., 2001; 11691787); in contrast, another study found that MSI-L status is associated with advanced stage and worse OS for patients with CRC (Esfahani et al., 2019; 30549036). MSI-L CRCs resemble MS-Stable tumors in most clinicopathologic features (Jass, 2007; 17204026, Lal et al., 2015; 25949894, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947) but harbor a significantly higher frequency of KRAS mutations than MS-Stable tumors (Jass et al., 1999; 10562815, Kambara et al., 2001; 11691787, Konishi et al., 1996; 8690195). MSS colorectal cancers are molecularly heterogeneous, driven by diverse mechanisms such as extensive DNA methylation, oncogenic mutations in KRAS or BRAF, or chromosomal instability (Jass, 2007; 17204026). On the basis of clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD-1-targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), retifanlimab, and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Shitara et al., 2022; 35322232, Andre et al., 2022; ASCO GI Abstract 244, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143, Berton et al., 2021; SITC Abstract 956), as well as PD-L1-targeting agents atezolizumab, avelumab, and durvalumab (alone or in combination with tremelimumab) (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92, Pietrantonio et al., 2023; ASCO GI Abstract 358, Lee et al., 2023; ASCO GI abstract 401, Rubinstein et al., 2022; 36512912, Marie et al., 2021; 33811152). Pembrolizumab therapy resulted in a significantly higher ORR in MSI-H CRC compared with MSS CRC (40% vs. 0%)(Le et al., 2015; 26028255). Similarly, a clinical study of nivolumab, alone or in combination with ipilimumab, in patients with CRC reported a significantly higher response rate in patients with tumors with high MSI than those without (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635). An earlier case study reported that nivolumab therapy resulted in a complete response in a patient with MSI-H CRC (Lipson et al., 2013; 23169436). A Phase 1b trial of atezolizumab combined with bevacizumab reported PRs for 40% (4/10) of patients with MSI-H CRC (Hochster et al., 2017; ASCO Abstract 673). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear. MSI has not been found to be a predictive biomarker for combination chemotherapy regimens, including FOLFOX (Sinicrope et al., 2013; 24019539, Gavin et al., 2012; 23045248) and FOLFIRI (Bertagnolli et al., 2009; 19273709, Van Cutsem et al., 2009; 19451425). Patients with MSS CRC are more likely to benefit from postsurgical fluorouracil (FU)-based adjuvant therapy (Ribic et al., 2003; 12867608, Sargent et al., 2010; 20498393) but less likely to benefit from irinotecan chemotherapy (Fallik et al., 2003; 14522894).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>NRAS</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>wildtype</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="wildtype" />
              </AlterationProperties>
              <Interpretation>NRAS encodes a member of the RAS family of small GTPases that mediate transduction of growth signals. Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF-MAPK-ERK, PI3K, and other pathways (Pylayeva-Gupta et al., 2011; 21993244). No alterations in NRAS were identified in this case. The majority of colorectal cancers (CRCs) (91-98%) have been reported to lack NRAS mutations (Pentheroudakis et al., 2013; 23374602, Vaughn et al., 2011; 21305640, Janku et al., 2013; 23400451, De Roock et al., 2010; 20619739, Irahara et al., 2010; 20736745, Cancer Genome Atlas Network., 2012; 22810696, Schirripa et al., 2015; 24806288, Guo et al., 2018; 29666387). NRAS wild-type status has been reported to be associated with decreased frequency of metastasis (Guo et al., 2018; 29666387) and longer survival (Schirripa et al., 2015; 24806288, Cercek et al., 2017; 28446505) of patients with CRC. Lack of mutations in KRAS or NRAS is associated with clinical benefit of treatment with EGFR-targeting antibodies cetuximab (Van Cutsem et al., 2011; 21502544, Bokemeyer et al., 2011; 21228335, Karapetis et al., 2008; 18946061, De Roock et al., 2008; 17998284) or panitumumab (Douillard et al., 2014; 24718886, Douillard et al., 2012; 24024839, Amado et al., 2008; 18316791) for patients with CRC. Therefore, these agents are indicated to treat patients with CRC lacking such mutations (NCCN Colon Cancer Guidelines, v3.2022, Rectal Cancer Guidelines, v4.2022).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies>
                <Therapy>
                  <Name />
                  <GenericName>Cetuximab</GenericName>
                  <FDAApproved>true</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Cetuximab is a monoclonal antibody that targets EGFR. It is FDA approved for the treatment of head and neck squamous cell carcinoma (HNSCC) and KRAS-wild-type, EGFR-expressing metastatic colorectal cancer (CRC). Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; Therapies targeting EGFR, including cetuximab, have been shown to have significant clinical activity for patients with CRC (Bokemeyer et al., 2011; 21228335, Cunningham et al., 2004; 15269313, De Roock et al., 2008; 17998284, Jonker et al., 2007; 18003960, Karapetis et al., 2008; 18946061, Van Cutsem et al., 2011; 21502544); wild-type KRAS and NRAS are predictive biomarkers for the efficacy of cetuximab in metastatic CRC (NCCN Colon Cancer Guidelines, v3.2022, NCCN Rectal Cancer Guidelines, v4.2022). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; Cetuximab has been shown to improve OS, PFS, and response rate for patients with KRAS-wildtype colorectal cancer (CRC), both in combination with FOLFIRI, FOLFOX4, or irinotecan (Van Cutsem et al., 2011; 21502544, Bokemeyer et al., 2011; 21228335, Jonker et al., 2007; 18003960, Cunningham et al., 2004; 15269313, Papamichael et al., 2022; 35033994) and as monotherapy for chemotherapy-refractory patients (De Roock et al., 2008; 17998284, Karapetis et al., 2014; 24218517). The Phase 3 study STRATEGIC-1 reported a similar duration of disease control (DDC) for patients with unresectable metastatic CRC (mCRC) and KRAS-, NRAS-, and BRAF-wildtype status treated with mFOLFOX-bevacizumab alternated with a cetuximab regimen in first or second line, respectively (overall DDC 22.5 vs. 23.5 months); in addition, the study reported similar OS (37.8 vs. 34.4 months) and higher numerical ORR for patients treated with cetuximab in the first line followed by mFOLFOX-bevacizumab compared with those receiving EGFR-directed antibodies in the second or third line (Chibaudel et al., 2022; ASCO Abstract 3504). A prospective study of cetuximab monotherapy for patients with KRAS-, NRAS-, and BRAF-wildtype mCRC reported 11% (2/19) PRs and 58% (11/19) SDs (Moiseyenko et al., 2018; 29470838). The Phase 2 AVETUX trial of cetuximab combined with avelumab and mFOLFOX6 for patients with RAS- and BRAF-wildtype mCRC resulted in an ORR of 81% (4 CR and 27 PRs, n=37) and a DCR of 89% (Stein et al., 2021; 34315821). In the Phase 3 ASPECCT study, panitumumab was found to be non-inferior to cetuximab with respect to median OS (10.4 vs. 10.0 months, HR=0.97) for patients with previously treated KRAS exon 2 wildtype metastatic colorectal cancer; median PFS was also similar between the two treatment groups (4.4 vs. 4.1 months, HR=1.00)(Price et al., 2014; 24739896). In a similar patient population, a Phase 2 study of combination panitumumab and irinotecan versus combination cetuximab and irinotecan also demonstrated non-inferiority with respect to median PFS (5.4 vs. 4.3 months, HR = 0.64) and median OS (14.9 vs. 11.5 months, HR=0.66)(Sakai et al., 2020; 32526634). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Panitumumab</GenericName>
                  <FDAApproved>true</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Panitumumab is a monoclonal antibody that targets EGFR. It is FDA approved to treat KRAS wild-type and NRAS wild-type metastatic colorectal cancer (CRC) combined with chemotherapy or as monotherapy for patients who have progressed on prior chemotherapy. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; Therapies targeting EGFR, including panitumumab, have been shown to have significant clinical activity for patients with CRC (Douillard et al., 2014; 24718886, Price et al., 2014; 24739896, Van Cutsem et al., 2007; 17470858); wild-type KRAS and NRAS are predictive biomarkers for the efficacy of panitumumab in metastatic CRC (NCCN Colon Cancer Guidelines v3.2022)(NCCN Rectal Cancers Guidelines, v4.2022). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; Panitumumab has been shown to improve OS, PFS, and ORR for patients with KRAS-wildtype colorectal cancer (CRC), both in combination with FOLFOX4, FOLFIRI, irinotecan, or best supportive care (Douillard et al., 2014; 24718886, Peeters et al., 2015; 26341920, Watanabe et al., 2022; 35723084, Kim et al., 2018; 29703606, Shitara et al., 2016; 27712015), and as monotherapy for chemotherapy-refractory patients (Price et al., 2014; 24739896, Van Cutsem et al., 2007; 17470858, Peeters et al., 2013; 23325582). The Phase 3 PARADIGM trial comparing panitumumab plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 as first-line treatment for patients with RAS-wildtype left-sided metastatic CRC demonstrated that treatment with panitumumab significantly improved median OS (mOS; 36.2 months vs. 31.3 months) compared with bevacizumab (Yoshino et al., 2022; ASCO Abstract LBA1). A Phase 2 trial reported that, for patients with unresectable RAS-wildtype colorectal adenocarcinoma treated with panitumumab plus FOLFOX4, maintenance with a combination of panitumumab plus fluorouracil and leucovorin was superior to panitumumab monotherapy (10-month PFS OF 59% vs. 49%)(Pietrantonio et al., 2019; 31268481). In the Phase 3 ASPECCT study, panitumumab was found to be non-inferior to cetuximab with respect to median OS (10.4 vs. 10.0 months, HR=0.97) for patients with previously treated KRAS exon 2 wildtype metastatic colorectal cancer; median PFS was also similar between the two treatment groups (4.4 vs. 4.1 months, HR=1.00)(Price et al., 2014; 24739896). In a similar patient population, a Phase 2 study of combination panitumumab and irinotecan versus combination cetuximab and irinotecan also demonstrated non-inferiority with respect to median PFS (5.4 vs. 4.3 months, HR = 0.64) and median OS (14.9 vs. 11.5 months, HR=0.66)(Sakai et al., 2020; 32526634). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
              </Therapies>
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>SMAD4</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>G386D</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="1.66" isEquivocal="false" name="G386D" />
              </AlterationProperties>
              <Interpretation>SMAD4, also known as DPC4, encodes a tumor suppressor that regulates transcriptional activity downstream of TGF-beta receptor signaling (Massague et al., 2012; 22992590, Massague et al., 2008; 18662538). SMAD4 alterations that result in loss or disruption of the MH1 domain (aa 18-142), MH2 domain (aa 323-552), or SAD domain (aa 275-320) are predicted to be inactivating (Massague et al., 2005; 16322555, MorÃ©n et al., 2000; 10980615, Xu and Attisano, 2000; 10781087, Luo et al., 1999; 10485843, Jones and Kern, 2000; 10871368, Fink et al., 2001; 11196171, De Bosscher et al., 2004; 14715079, Shi et al., 1997; 9214508, Miyaki et al., 1999; 10340381, Prokova et al., 2007; 17994767, Wu et al., 2001; 11274206, Ding et al., 2009; 19139564, Kuang et al., 2004; 14647410, Watanabe et al., 2000; 11265759, Bosscher et al., 2004; 14715079). SMAD4 mutation or homozygous deletion is most frequently observed in pancreatic adenocarcinoma (43%)(cBio-Witkiewicz et al., 2015; 25855536), pancreatic acinar cell carcinoma (26%)(Jiao et al., 2014; 24293293), cholangiocarcinoma (25%)(Churi et al., 2014; 25536104), small intestine cancer (20%) (Takeda et al., 2022; ASCO GI Abstract 642), appendiceal adenocarcinoma (14-20% mutation; 57% deletion)(Liu et al., 2014; 24821835, Maru et al., 2004; 14647445), colorectal adenocarcinoma (CRC; 14%)(Cancer Genome Atlas Network., 2012; 22810696), esophageal adenocarcinoma (14%)(Wang et al., 2015; 26336083), and stomach adenocarcinoma (13%)(Cancer Genome Atlas Research Network., 2014; 25079317). In preclinical studies, SMAD4 loss of function has been implicated in the development of mucinous neoplasms of the pancreas, including mucinous cystic neoplasms (MCN)(Izeradjene et al., 2007; 17349581) and intraductal papillary mucinous neoplasms (IPMN)(Bardeesy et al., 2006; 17114584); in clinical samples, SMAD4 homozygous deletion has been observed in 10% of IPMNs and 8% of MCNs, and mutation was also observed in 5% of IPMNs (Springer et al., 2015; 26253305). SMAD4 gene alterations have been associated with reduced OS for patients with pancreatic adenocarcinoma (Blackford et al., 2009; 19584151). Reduced SMAD4 expression has been associated with worse prognosis in various cancer types, including CRC (Yan et al., 2016; 26861460, Kozak et al., 2015; 25681512, Roth et al., 2012; 23104212), appendiceal mucinous neoplasm (Davison et al., 2014; 24618609), gastric adenocarcinoma (Kim et al., 2004; 15033661, Xiangming et al., 2001; 11234879), esophageal adenocarcinoma (Singhi et al., 2015; 25634752), esophageal squamous cell carcinoma (Natsugoe et al., 2002; 12060625), breast cancer (de Kruijf et al., 2013; 23022998), and prostate cancer (Shipitsin et al., 2014; 25032733). There are no targeted therapies available to address genomic alterations in SMAD4. Preclinical studies in colorectal cancer have reported associations of SMAD4 inactivation or loss with sensitivity to inhibitors of Aurora kinase A (Shi et al., 2022; 35393542) and the Wnt/beta-catenin pathway (Park et al., 2022; 35274815). Clinical studies have reported associations of SMAD4 loss or low SMAD4 expression with improved responses to chemotherapeutic agents in patients with pancreatic cancer (Ormanns et al., 2017; 28534865, Fei et al., 2021; 34002944, Bachet et al., 2012; 22377565) and non-small cell lung cancer (NSCLC) (Ziemke et al., 2017; 28577946). Other clinical studies in pancreatic cancer have reported an association of high SMAD4 expression with better responses to neoadjuvant chemotherapy (Kassardjian and Wang, 2020; 32897998) and adjuvant chemoradiotherapy (Pen et al., 2021; 33667587). Germline SMAD4 mutations, including those at the R361 hotspot, have been observed in patients with juvenile polyposis syndrome (Houlston et al., 1998; 9811934, Woodford-Richens et al., 2000; 10764709, Howe et al., 2004; 15235019, Howe et al., 2004; 15235019, Howe et al., 2004; 15235019), which is associated with an increased risk of gastrointestinal cancers (Brosens et al., 2011; 22171123). The penetrance of deleterious SMAD4 mutations in patients with colon cancer is estimated at 20% by age 35 and 70% by age 65 (Kalia et al., 2017; 27854360). In the appropriate clinical context, germline testing of SMAD4 is recommended.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>Tumor Mutation Burden</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>Cannot Be Determined</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="Cannot Be Determined" />
              </AlterationProperties>
              <Interpretation>Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide-based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). Elevated TMB has been reported to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors in multiple solid tumor types (Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915). However, the TMB level in this sample could not be determined with confidence. Elevated tumor mutational burden (TMB) has been reported in 8-25% of colorectal cancer (CRC) samples (George et al., 2016; ASCO Abstract 3587, Nagahashi et al., 2016; ASCO Abstract e15103, Cancer Genome Atlas Network, 2012; 22810696, Stadler et al., 2016; 27022117, Shao et al., 2020; 33119110). Multiple studies have reported that up to 90% of hypermutated CRC cases exhibit high levels of microsatellite instability (MSI-H) and mismatch repair deficiency (MMR-D) (Cancer Genome Atlas Network, 2012; 22810696, Stadler et al., 2016; 27022117). Increased TMB is significantly associated with MSI-H and MMR-D, with studies reporting that 100% of MSI-H CRCs harbor elevated TMB and conversely that 100% of tumors with low TMB harbor intact MMR (George et al., 2016; ASCO Abstract 3587, Nagahashi et al., 2016; ASCO Abstract e15103, Stadler et al., 2016; 27022117). A subset of CRCs that harbor increased TMB but not MSI-H are driven by mutations in POLE, which leads to an âultramutatedâ phenotype with especially high TMB (Cancer Genome Atlas Network, 2012; 22810696, Stadler et al., 2016; 27022117). Tumors with increased TMB harbor BRAF V600E mutations more frequently than those with low TMB (Cancer Genome Atlas Network, 2012; 22810696, Stadler et al., 2016; 27022117), whereas TMB-low tumors more frequently harbor mutations in TP53 and APC (Cancer Genome Atlas Network, 2012; 22810696). The prognostic value of tumor mutational burden (TMB) in colorectal cancer (CRC) is context- and therapy-dependent. A study of tissue TMB (tTMB) in 145 CRC samples showed longer OS in TMB-high samples compared with TMB-low ones (Schwartz et al., 2018; ASCO Abstract 572). Similarly, for patients with metastatic CRC treated with first-line chemotherapy combined with bevacizumab or cetuximab, high tissue TMB (tTMB-H) was associated with longer OS (Innocenti et al., 2019; 30865548). For patients treated with adjuvant chemotherapy, tTMB-H was associated with better 5-year relapse-free survival (Lee et al., 2019; 31285374). However, for patients with EGFR/BRAF-inhibitor-treated, BRAF-mutated microsatellite stable (MSS) metastatic CRC, intermediate tTMB was associated with significantly poorer PFS and OS compared with TMB-low status; patients with primary resistance to EGFR/BRAF blockage had higher TMB than those sensitive to these therapies (Randon et al., 2022; 34933155). In a study for 61 patients with metastatic, MSS CRC treated with best standard of care, plasma TMB scores â¥28 Muts/Mb (approximately 14 Muts/Mb as measured by this assay) were associated with reduced OS compared with plasma TMB scores &lt;28 Muts/Mb (3.0 vs. 5.3 months, HR=0.76, p=0.007), whereas tTMB was not found to be prognostic in this population (Chen et al., 2020; 32379280, Loree et al., 2021; ASCO GI Abstract 61). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti-PD-1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan-tumor studies, increased tissue tumor mutational burden (TMB) was associated with sensitivity to immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Ott et al., 2019; 30557521, Cristescu et al., 2022; 35101941, Friedman et al., 2022; 34876409, Sturgill et al., 2022; 35274716). In the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors, significant improvement in ORR was observed for patients with TMB â¥10 Muts/Mb (as measured by this assay) compared with those with TMB &lt;10 Muts/Mb in a large cohort that included multiple tumor types (Marabelle et al., 2020; 32919526); similar findings were observed in the KEYNOTE 028 and 012 trials (Cristescu et al., 2018; 30309915). At the same TMB cutpoint, retrospective analysis of patients with solid tumors treated with any checkpoint inhibitor identified that tissue TMB scores â¥ 10 Muts/Mb were associated with prolonged time to treatment failure compared with scores &lt;10 muts/Mb (HR=0.68) (Sturgill et al., 2022; 35274716). For patients with solid tumors treated with nivolumab plus ipilimumab in the CheckMate 848 trial, improved responses were observed in patients with a tissue TMB â¥ 10 Muts/Mb independent of blood TMB at any cutpoint in matched samples (Schenker at al., 2022; AACR Abstract 7845). However, support for higher TMB thresholds and efficacy was observed in the prospective Phase 2 MyPathway trial of atezolizumab for patients with pan-solid tumors, where improved ORR and DCR was seen in patients with TMB â¥ 16 Muts/Mb than those with TMB â¥ 10 and &lt;16 Muts/Mb (Friedman et al., 2022; 34876409). Similarly, analyses across several solid tumor types reported that patients with higher TMB (defined as â¥16-20 Muts/Mb) achieved greater clinical benefit from PD-1 or PD-L1-targeting monotherapy compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD-1 or PD-L1-targeting agents (Goodman et al., 2017; 28835386). In CRC specifically, a retrospective analysis of immune checkpoint inhibitor efficacy reported significantly improved OS for patients with tumors harboring TMB â¥9.8 Muts/MB compared with those with tumors with TMB &lt;9.8 Muts/Mb (~ equivalency &lt;12 Muts/Mb as measured by this assay) (Samstein et al., 2019; 30643254). Another retrospective study reported that a TMB â¥12 Muts/Mb cutoff identifies &gt;99% of MSI-High CRC cases but only 3% of MSS cases, indicating the utility of this cutoff for identification of patients with CRC likely to benefit from treatment with immune checkpoint inhibitors (Fabrizio et al., 2018; 30151257). As the TMB status of this tumor cannot be determined with confidence, the benefit of these therapeutic approaches is unclear.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
      </Genes>
      <Trials />
      <References>
        <Reference number="0">
          <ReferenceId>21993244</ReferenceId>
          <FullCitation>Pylayeva-Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="1">
          <ReferenceId>23374602</ReferenceId>
          <FullCitation>Pentheroudakis G, et al. BMC Cancer (2013) pmid: 23374602</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="2">
          <ReferenceId>21305640</ReferenceId>
          <FullCitation>Vaughn CP, et al. Genes Chromosomes Cancer (2011) pmid: 21305640</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="3">
          <ReferenceId>23400451</ReferenceId>
          <FullCitation>Janku F, et al. Target Oncol (2013) pmid: 23400451</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="4">
          <ReferenceId>20619739</ReferenceId>
          <FullCitation>De Roock W, et al. Lancet Oncol. (2010) pmid: 20619739</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="5">
          <ReferenceId>20736745</ReferenceId>
          <FullCitation>Irahara N, et al. Diagn. Mol. Pathol. (2010) pmid: 20736745</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="6">
          <ReferenceId>22810696</ReferenceId>
          <FullCitation>Nature (2012) pmid: 22810696</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="7">
          <ReferenceId>24806288</ReferenceId>
          <FullCitation>Schirripa M, et al. Int. J. Cancer (2015) pmid: 24806288</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="8">
          <ReferenceId>29666387</ReferenceId>
          <FullCitation>Guo F, et al. Sci Rep (2018) pmid: 29666387</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="9">
          <ReferenceId>28446505</ReferenceId>
          <FullCitation>Cercek A, et al. Clin. Cancer Res. (2017) pmid: 28446505</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="10">
          <ReferenceId>21502544</ReferenceId>
          <FullCitation>Van Cutsem E, et al. J. Clin. Oncol. (2011) pmid: 21502544</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="11">
          <ReferenceId>21228335</ReferenceId>
          <FullCitation>Bokemeyer C, et al. Ann. Oncol. (2011) pmid: 21228335</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="12">
          <ReferenceId>18946061</ReferenceId>
          <FullCitation>Karapetis CS, et al. N. Engl. J. Med. (2008) pmid: 18946061</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="13">
          <ReferenceId>17998284</ReferenceId>
          <FullCitation>De Roock W, et al. Ann. Oncol. (2008) pmid: 17998284</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="14">
          <ReferenceId>24718886</ReferenceId>
          <FullCitation>Douillard JY, et al. Ann. Oncol. (2014) pmid: 24718886</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="15">
          <ReferenceId>24024839</ReferenceId>
          <FullCitation>Douillard JY, et al. N. Engl. J. Med. (2013) pmid: 24024839</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="16">
          <ReferenceId>18316791</ReferenceId>
          <FullCitation>Amado RG, et al. J. Clin. Oncol. (2008) pmid: 18316791</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="17">
          <ReferenceId>15748635</ReferenceId>
          <FullCitation>Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="18">
          <ReferenceId>23875803</ReferenceId>
          <FullCitation>Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="19">
          <ReferenceId>12379884</ReferenceId>
          <FullCitation>Pfeifer GP, et al. Oncogene (2002) pmid: 12379884</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="20">
          <ReferenceId>25765070</ReferenceId>
          <FullCitation>Rizvi NA, et al. Science (2015) pmid: 25765070</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="21">
          <ReferenceId>24336570</ReferenceId>
          <FullCitation>Johnson BE, et al. Science (2014) pmid: 24336570</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="22">
          <ReferenceId>29452419</ReferenceId>
          <FullCitation>Choi S, et al. Neuro-oncology (2018) pmid: 29452419</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="23">
          <ReferenceId>23636398</ReferenceId>
          <FullCitation>Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="24">
          <ReferenceId>23447401</ReferenceId>
          <FullCitation>Briggs S, et al. J. Pathol. (2013) pmid: 23447401</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="25">
          <ReferenceId>24583393</ReferenceId>
          <FullCitation>Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="26">
          <ReferenceId>25568919</ReferenceId>
          <FullCitation>Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="27">
          <ReferenceId>32919526</ReferenceId>
          <FullCitation>Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="28">
          <ReferenceId>31405947</ReferenceId>
          <FullCitation>Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="29">
          <ReferenceId>28835386</ReferenceId>
          <FullCitation>Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="30">
          <ReferenceId>30309915</ReferenceId>
          <FullCitation>Cristescu R, et al. Science (2018) pmid: 30309915</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="31">
          <ReferenceId>27022117</ReferenceId>
          <FullCitation>Stadler ZK, et al. J. Clin. Oncol. (2016) pmid: 27022117</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="32">
          <ReferenceId>33119110</ReferenceId>
          <FullCitation>Shao C, et al. JAMA Netw Open (2020) pmid: 33119110</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="33">
          <ReferenceId>30865548</ReferenceId>
          <FullCitation>Innocenti F, et al. J Clin Oncol (2019) pmid: 30865548</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="34">
          <ReferenceId>31285374</ReferenceId>
          <FullCitation>Lee DW, et al. Clin Cancer Res (2019) pmid: 31285374</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="35">
          <ReferenceId>34933155</ReferenceId>
          <FullCitation>Randon G, et al. Eur J Cancer (2022) pmid: 34933155</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="36">
          <ReferenceId>32379280</ReferenceId>
          <FullCitation>Chen EX, et al. JAMA Oncol (2020) pmid: 32379280</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="37">
          <ReferenceId>30643254</ReferenceId>
          <FullCitation>Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="38">
          <ReferenceId>30785829</ReferenceId>
          <FullCitation>Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="39">
          <ReferenceId>29658845</ReferenceId>
          <FullCitation>Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="40">
          <ReferenceId>29657128</ReferenceId>
          <FullCitation>Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="41">
          <ReferenceId>29731394</ReferenceId>
          <FullCitation>Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="42">
          <ReferenceId>33558721</ReferenceId>
          <FullCitation>Rozeman EA, et al. Nat Med (2021) pmid: 33558721</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="43">
          <ReferenceId>32916128</ReferenceId>
          <FullCitation>Sharma P, et al. Cancer Cell (2020) pmid: 32916128</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="44">
          <ReferenceId>30557521</ReferenceId>
          <FullCitation>Ott PA, et al. J. Clin. Oncol. (2019) pmid: 30557521</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="45">
          <ReferenceId>35101941</ReferenceId>
          <FullCitation>Cristescu R, et al. J Immunother Cancer (2022) pmid: 35101941</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="46">
          <ReferenceId>34876409</ReferenceId>
          <FullCitation>Friedman CF, et al. Cancer Discov (2022) pmid: 34876409</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="47">
          <ReferenceId>35274716</ReferenceId>
          <FullCitation>Sturgill EG, et al. Oncologist (2022) pmid: 35274716</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="48">
          <ReferenceId>30151257</ReferenceId>
          <FullCitation>Fabrizio DA, et al. J Gastrointest Oncol (2018) pmid: 30151257</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="49">
          <ReferenceId>3310850</ReferenceId>
          <FullCitation>Kahn S, et al. Anticancer Res. () pmid: 3310850</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="50">
          <ReferenceId>16618717</ReferenceId>
          <FullCitation>LiÃ¨vre A, et al. Cancer Res. (2006) pmid: 16618717</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="51">
          <ReferenceId>21163703</ReferenceId>
          <FullCitation>De Roock W, et al. Lancet Oncol. (2011) pmid: 21163703</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="52">
          <ReferenceId>25367198</ReferenceId>
          <FullCitation>Chen J, et al. BMC Cancer (2014) pmid: 25367198</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="53">
          <ReferenceId>25929517</ReferenceId>
          <FullCitation>Li W, et al. BMC Cancer (2015) pmid: 25929517</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="54">
          <ReferenceId>27977612</ReferenceId>
          <FullCitation>Hu J, et al. Medicine (Baltimore) (2016) pmid: 27977612</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="55">
          <ReferenceId>28218784</ReferenceId>
          <FullCitation>Zekri J, et al. Genet. Mol. Res. (2017) pmid: 28218784</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="56">
          <ReferenceId>29048416</ReferenceId>
          <FullCitation>Staudacher JJ, et al. Clin Transl Gastroenterol (2017) pmid: 29048416</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="57">
          <ReferenceId>29705968</ReferenceId>
          <FullCitation>Wang Y, et al. Virchows Arch. (2018) pmid: 29705968</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="58">
          <ReferenceId>28106826</ReferenceId>
          <FullCitation>MÃ¡rmol I, et al. Int J Mol Sci (2017) pmid: 28106826</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="59">
          <ReferenceId>28858102</ReferenceId>
          <FullCitation>Kwak MS, et al. Medicine (Baltimore) (2017) pmid: 28858102</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="60">
          <ReferenceId>26337942</ReferenceId>
          <FullCitation>Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="61">
          <ReferenceId>21081928</ReferenceId>
          <FullCitation>You JF, et al. Br. J. Cancer (2010) pmid: 21081928</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="62">
          <ReferenceId>24623249</ReferenceId>
          <FullCitation>Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="63">
          <ReferenceId>10562815</ReferenceId>
          <FullCitation>Jass JR, et al. J. Clin. Pathol. (1999) pmid: 10562815</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="64">
          <ReferenceId>20627535</ReferenceId>
          <FullCitation>Guastadisegni C, et al. Eur. J. Cancer (2010) pmid: 20627535</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="65">
          <ReferenceId>15528785</ReferenceId>
          <FullCitation>Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="66">
          <ReferenceId>25949894</ReferenceId>
          <FullCitation>Lal N, et al. Oncoimmunology (2015) pmid: 25949894</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="67">
          <ReferenceId>11535541</ReferenceId>
          <FullCitation>Samowitz WS, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11535541</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="68">
          <ReferenceId>12445368</ReferenceId>
          <FullCitation>Elsaleh H, et al. Clin Colorectal Cancer (2001) pmid: 12445368</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="69">
          <ReferenceId>12820457</ReferenceId>
          <FullCitation>Brueckl WM, et al. Anticancer Res. () pmid: 12820457</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="70">
          <ReferenceId>11438476</ReferenceId>
          <FullCitation>Guidoboni M, et al. Am. J. Pathol. (2001) pmid: 11438476</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="71">
          <ReferenceId>10631274</ReferenceId>
          <FullCitation>Gryfe R, et al. N. Engl. J. Med. (2000) pmid: 10631274</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="72">
          <ReferenceId>16952542</ReferenceId>
          <FullCitation>Sinicrope FA, et al. Gastroenterology (2006) pmid: 16952542</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="73">
          <ReferenceId>22722556</ReferenceId>
          <FullCitation>Laghi L, et al. Dig Dis (2012) pmid: 22722556</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="74">
          <ReferenceId>20420947</ReferenceId>
          <FullCitation>Boland CR, et al. Gastroenterology (2010) pmid: 20420947</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="75">
          <ReferenceId>11691787</ReferenceId>
          <FullCitation>Kambara T, et al. Cancer Res. (2001) pmid: 11691787</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="76">
          <ReferenceId>30549036</ReferenceId>
          <FullCitation>Torshizi Esfahani A, et al. J Cell Physiol (2019) pmid: 30549036</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="77">
          <ReferenceId>17204026</ReferenceId>
          <FullCitation>Histopathology (2007) pmid: 17204026</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="78">
          <ReferenceId>8690195</ReferenceId>
          <FullCitation>Konishi M, et al. Gastroenterology (1996) pmid: 8690195</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="79">
          <ReferenceId>28734759</ReferenceId>
          <FullCitation>Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="80">
          <ReferenceId>29355075</ReferenceId>
          <FullCitation>Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="81">
          <ReferenceId>35322232</ReferenceId>
          <FullCitation>Shitara K, et al. Nature (2022) pmid: 35322232</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="82">
          <ReferenceId>23169436</ReferenceId>
          <FullCitation>Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="83">
          <ReferenceId>26028255</ReferenceId>
          <FullCitation>Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="84">
          <ReferenceId>33001143</ReferenceId>
          <FullCitation>Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="85">
          <ReferenceId>36512912</ReferenceId>
          <FullCitation>Rubinstein MM, et al. Gynecol Oncol (2022) pmid: 36512912</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="86">
          <ReferenceId>33811152</ReferenceId>
          <FullCitation>Kanikarla Marie P, et al. Clin Cancer Res (2021) pmid: 33811152</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="87">
          <ReferenceId>24019539</ReferenceId>
          <FullCitation>Sinicrope FA, et al. J. Clin. Oncol. (2013) pmid: 24019539</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="88">
          <ReferenceId>23045248</ReferenceId>
          <FullCitation>Gavin PG, et al. Clin. Cancer Res. (2012) pmid: 23045248</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="89">
          <ReferenceId>19273709</ReferenceId>
          <FullCitation>Bertagnolli MM, et al. J. Clin. Oncol. (2009) pmid: 19273709</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="90">
          <ReferenceId>19451425</ReferenceId>
          <FullCitation>Van Cutsem E, et al. J. Clin. Oncol. (2009) pmid: 19451425</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="91">
          <ReferenceId>12867608</ReferenceId>
          <FullCitation>Ribic CM, et al. N. Engl. J. Med. (2003) pmid: 12867608</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="92">
          <ReferenceId>20498393</ReferenceId>
          <FullCitation>Sargent DJ, et al. J. Clin. Oncol. (2010) pmid: 20498393</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="93">
          <ReferenceId>14522894</ReferenceId>
          <FullCitation>Fallik D, et al. Cancer Res. (2003) pmid: 14522894</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="94">
          <ReferenceId>22992590</ReferenceId>
          <FullCitation>Nat. Rev. Mol. Cell Biol. (2012) pmid: 22992590</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="95">
          <ReferenceId>18662538</ReferenceId>
          <FullCitation>Cell (2008) pmid: 18662538</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="96">
          <ReferenceId>16322555</ReferenceId>
          <FullCitation>MassaguÃ© J, et al. Genes Dev. (2005) pmid: 16322555</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="97">
          <ReferenceId>10980615</ReferenceId>
          <FullCitation>MorÃ©n A, et al. Oncogene (2000) pmid: 10980615</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="98">
          <ReferenceId>10781087</ReferenceId>
          <FullCitation>Xu J, et al. Proc. Natl. Acad. Sci. U.S.A. (2000) pmid: 10781087</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="99">
          <ReferenceId>10485843</ReferenceId>
          <FullCitation>Luo K, et al. Genes Dev. (1999) pmid: 10485843</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="100">
          <ReferenceId>10871368</ReferenceId>
          <FullCitation>Jones JB, et al. Nucleic Acids Res. (2000) pmid: 10871368</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="101">
          <ReferenceId>11196171</ReferenceId>
          <FullCitation>Fink SP, et al. Cancer Res. (2001) pmid: 11196171</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="102">
          <ReferenceId>14715079</ReferenceId>
          <FullCitation>De Bosscher K, et al. Biochem. J. (2004) pmid: 14715079</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="103">
          <ReferenceId>9214508</ReferenceId>
          <FullCitation>Shi Y, et al. Nature (1997) pmid: 9214508</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="104">
          <ReferenceId>10340381</ReferenceId>
          <FullCitation>Miyaki M, et al. Oncogene (1999) pmid: 10340381</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="105">
          <ReferenceId>17994767</ReferenceId>
          <FullCitation>Prokova V, et al. Biochemistry (2007) pmid: 17994767</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="106">
          <ReferenceId>11274206</ReferenceId>
          <FullCitation>Wu JW, et al. J. Biol. Chem. (2001) pmid: 11274206</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="107">
          <ReferenceId>19139564</ReferenceId>
          <FullCitation>Ding L, et al. J. Clin. Invest. (2009) pmid: 19139564</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="108">
          <ReferenceId>14647410</ReferenceId>
          <FullCitation>Kuang C, et al. Oncogene (2004) pmid: 14647410</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="109">
          <ReferenceId>11265759</ReferenceId>
          <FullCitation>Watanabe M, et al. EMBO Rep. (2000) pmid: 11265759</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="110">
          <ReferenceId>25855536</ReferenceId>
          <FullCitation>Witkiewicz AK, et al. Nat Commun (2015) pmid: 25855536</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="111">
          <ReferenceId>24293293</ReferenceId>
          <FullCitation>Jiao Y, et al. J. Pathol. (2014) pmid: 24293293</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="112">
          <ReferenceId>25536104</ReferenceId>
          <FullCitation>Churi CR, et al. PLoS ONE (2014) pmid: 25536104</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="113">
          <ReferenceId>24821835</ReferenceId>
          <FullCitation>Liu X, et al. Clin. Chem. (2014) pmid: 24821835</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="114">
          <ReferenceId>14647445</ReferenceId>
          <FullCitation>Maru D, et al. Oncogene (2004) pmid: 14647445</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="115">
          <ReferenceId>26336083</ReferenceId>
          <FullCitation>Wang K, et al. Oncologist (2015) pmid: 26336083</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="116">
          <ReferenceId>25079317</ReferenceId>
          <FullCitation>Nature (2014) pmid: 25079317</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="117">
          <ReferenceId>17349581</ReferenceId>
          <FullCitation>Izeradjene K, et al. Cancer Cell (2007) pmid: 17349581</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="118">
          <ReferenceId>17114584</ReferenceId>
          <FullCitation>Bardeesy N, et al. Genes Dev. (2006) pmid: 17114584</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="119">
          <ReferenceId>26253305</ReferenceId>
          <FullCitation>Springer S, et al. Gastroenterology (2015) pmid: 26253305</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="120">
          <ReferenceId>19584151</ReferenceId>
          <FullCitation>Blackford A, et al. Clin. Cancer Res. (2009) pmid: 19584151</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="121">
          <ReferenceId>26861460</ReferenceId>
          <FullCitation>Yan P, et al. Clin. Cancer Res. (2016) pmid: 26861460</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="122">
          <ReferenceId>25681512</ReferenceId>
          <FullCitation>Kozak MM, et al. J. Clin. Pathol. (2015) pmid: 25681512</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="123">
          <ReferenceId>23104212</ReferenceId>
          <FullCitation>Roth AD, et al. J. Natl. Cancer Inst. (2012) pmid: 23104212</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="124">
          <ReferenceId>24618609</ReferenceId>
          <FullCitation>Davison JM, et al. Am. J. Surg. Pathol. (2014) pmid: 24618609</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="125">
          <ReferenceId>15033661</ReferenceId>
          <FullCitation>Kim YH, et al. Ann. Oncol. (2004) pmid: 15033661</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="126">
          <ReferenceId>11234879</ReferenceId>
          <FullCitation>Xiangming C, et al. Clin. Cancer Res. (2001) pmid: 11234879</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="127">
          <ReferenceId>25634752</ReferenceId>
          <FullCitation>Singhi AD, et al. Am. J. Surg. Pathol. (2015) pmid: 25634752</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="128">
          <ReferenceId>12060625</ReferenceId>
          <FullCitation>Natsugoe S, et al. Clin. Cancer Res. (2002) pmid: 12060625</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="129">
          <ReferenceId>23022998</ReferenceId>
          <FullCitation>de Kruijf EM, et al. Ann. Oncol. (2013) pmid: 23022998</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="130">
          <ReferenceId>25032733</ReferenceId>
          <FullCitation>Shipitsin M, et al. Br. J. Cancer (2014) pmid: 25032733</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="131">
          <ReferenceId>35393542</ReferenceId>
          <FullCitation>Shi C, et al. Oncogene (2022) pmid: 35393542</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="132">
          <ReferenceId>35274815</ReferenceId>
          <FullCitation>Park JW, et al. Cancer Med (2022) pmid: 35274815</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="133">
          <ReferenceId>28534865</ReferenceId>
          <FullCitation>Ormanns S, et al. Int J Mol Sci (2017) pmid: 28534865</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="134">
          <ReferenceId>34002944</ReferenceId>
          <FullCitation>Fei N, et al. Clin Transl Sci (2021) pmid: 34002944</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="135">
          <ReferenceId>22377565</ReferenceId>
          <FullCitation>Bachet JB, et al. Ann. Oncol. (2012) pmid: 22377565</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="136">
          <ReferenceId>28577946</ReferenceId>
          <FullCitation>Ziemke M, et al. Lung Cancer (2017) pmid: 28577946</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="137">
          <ReferenceId>32897998</ReferenceId>
          <FullCitation>Kassardjian A, et al. Pancreas (2020) pmid: 32897998</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="138">
          <ReferenceId>33667587</ReferenceId>
          <FullCitation>Pen SL, et al. Radiother Oncol (2021) pmid: 33667587</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="139">
          <ReferenceId>9811934</ReferenceId>
          <FullCitation>Houlston R, et al. Hum. Mol. Genet. (1998) pmid: 9811934</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="140">
          <ReferenceId>10764709</ReferenceId>
          <FullCitation>Woodford-Richens K, et al. Gut (2000) pmid: 10764709</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="141">
          <ReferenceId>15235019</ReferenceId>
          <FullCitation>Howe JR, et al. J. Med. Genet. (2004) pmid: 15235019</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="142">
          <ReferenceId>22171123</ReferenceId>
          <FullCitation>Brosens LA, et al. World J. Gastroenterol. (2011) pmid: 22171123</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="143">
          <ReferenceId>27854360</ReferenceId>
          <FullCitation>Kalia SS, et al. Genet. Med. (2017) pmid: 27854360</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="144">
          <ReferenceId>24739896</ReferenceId>
          <FullCitation>Price TJ, et al. Lancet Oncol. (2014) pmid: 24739896</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="145">
          <ReferenceId>32526634</ReferenceId>
          <FullCitation>Sakai D, et al. Eur J Cancer (2020) pmid: 32526634</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="146">
          <ReferenceId>18003960</ReferenceId>
          <FullCitation>Jonker DJ, et al. N. Engl. J. Med. (2007) pmid: 18003960</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="147">
          <ReferenceId>15269313</ReferenceId>
          <FullCitation>Cunningham D, et al. N. Engl. J. Med. (2004) pmid: 15269313</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="148">
          <ReferenceId>35033994</ReferenceId>
          <FullCitation>Papamichael D, et al. Eur J Cancer (2022) pmid: 35033994</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="149">
          <ReferenceId>24218517</ReferenceId>
          <FullCitation>Karapetis CS, et al. Clin. Cancer Res. (2014) pmid: 24218517</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="150">
          <ReferenceId>29470838</ReferenceId>
          <FullCitation>Moiseyenko VM, et al. Clin Drug Investig (2018) pmid: 29470838</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="151">
          <ReferenceId>34315821</ReferenceId>
          <FullCitation>Stein A, et al. J Immunother Cancer (2021) pmid: 34315821</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="152">
          <ReferenceId>26341920</ReferenceId>
          <FullCitation>Peeters M, et al. Clin. Cancer Res. (2015) pmid: 26341920</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="153">
          <ReferenceId>35723084</ReferenceId>
          <FullCitation>Watanabe J, et al. Int J Cancer (2022) pmid: 35723084</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="154">
          <ReferenceId>29703606</ReferenceId>
          <FullCitation>Kim TW, et al. Clin Colorectal Cancer (2018) pmid: 29703606</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="155">
          <ReferenceId>27712015</ReferenceId>
          <FullCitation>Shitara K, et al. Cancer Sci (2016) pmid: 27712015</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="156">
          <ReferenceId>17470858</ReferenceId>
          <FullCitation>Van Cutsem E, et al. J. Clin. Oncol. (2007) pmid: 17470858</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="157">
          <ReferenceId>23325582</ReferenceId>
          <FullCitation>Peeters M, et al. Clin. Cancer Res. (2013) pmid: 23325582</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="158">
          <ReferenceId>31268481</ReferenceId>
          <FullCitation>Pietrantonio F, et al. JAMA Oncol (2019) pmid: 31268481</FullCitation>
          <Include>true</Include>
        </Reference>
      </References>
      <Signatures>
        <Signature>
          <ServerTime>2023-07-14 16:06:07</ServerTime>
          <OpName>Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director</OpName>
          <Text>Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director</Text>
        </Signature>
      </Signatures>
      <reportProperties>
        <reportProperty identifier="QualityControlMetrics" key="MedianCoverageValue">
          <value>940x</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="TumorMutationBurdenScore">
          <value>0 Muts/Mb</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="MicrosatelliteStatusScore">
          <value>0 fraction-unstable-loci</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="LossOfHeterozygosityScore">
          <value>Units Not Reported</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="BloodTumorMutationalBurdenScore">
          <value>Units Not Reported</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="TumorFractionScore">
          <value>Units Not Reported</value>
        </reportProperty>
      </reportProperties>
      <comments />
      <AAC>
        <Amendmends />
      </AAC>
    </FinalReport>
    <variant-report xmlns="http://foundationmedicine.com/compbio/variant-report-external" disease="COLON" disease-ontology="Colon adenocarcinoma (CRC)" flowcell-analysis="2000030034" gender="female" pathology-diagnosis="Colon Adenocarcinoma" percent-tumor-nuclei="20" pipeline-version="v3.23.0" purity-assessment="4.56" specimen="ORD-1667994-01*US1589887.01" study="FMI RCH F1CDx Eval Comp Use v2" test-request="ORD-1667994-01" test-type="FoundationOneDx" tissue-of-origin="Ovary" xsi:schemaLocation="http://foundationmedicine.com/compbio/variant-report-external http://integration.foundationmedicine.com/reporting/variant-report-external-2.2.xsd">
      <samples>
        <sample bait-set="DX2" mean-exon-depth="957.64" name="SQ-US1589887.01-1" nucleic-acid-type="DNA" />
      </samples>
      <quality-control status="Qualified" />
      <short-variants>
        <short-variant allele-fraction="0.0166" cds-effect="1157G&gt;A" depth="783" equivocal="false" functional-effect="missense" gene="SMAD4" percent-reads="1.66" position="chr18:48593406" protein-effect="G386D" status="known" strand="+" transcript="NM_005359">
          <dna-evidence sample="SQ-US1589887.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.5243" cds-effect="1960C&gt;G" depth="925" equivocal="false" functional-effect="missense" gene="TSC1" percent-reads="52.43" position="chr9:135781005" protein-effect="Q654E" status="unknown" strand="-" transcript="NM_000368">
          <dna-evidence sample="SQ-US1589887.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.4897" cds-effect="4071_4072insGATT" depth="388" equivocal="false" functional-effect="frameshift" gene="MSH6" percent-reads="48.97" position="chr2:48033987" protein-effect="K1358fs*2" status="unknown" strand="+" transcript="NM_000179">
          <dna-evidence sample="SQ-US1589887.01-1" />
        </short-variant>
      </short-variants>
      <copy-number-alterations />
      <rearrangements />
      <biomarkers>
        <microsatellite-instability status="unknown" />
        <tumor-mutation-burden score="0.0" status="unknown" unit="mutations-per-megabase" />
      </biomarkers>
      <non-human-content />
    </variant-report>
  </rr:ResultsPayload>
</rr:ResultsReport>
